The global Wilson’s Disease Treatment Market is estimated to be valued at US$ 560.2 Mn or in 2023 and is expected to exhibit a CAGR of 6.3% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Wilson’s disease is a rare genetic condition that causes excessive copper to accumulate in the liver and other vital organs. Symptoms can range from mild to severe depending on which parts of the body are affected. Common treatments include chelation therapy, which removes copper from the body, and management of symptoms through medication.
Market key trends:
One of the key trends in the Wilson’s Disease Treatment Market is the increased focus on development of new therapeutic agents with improved efficacy and safety profiles over existing standard of care drugs. Currently, penicillamine is the most common first line treatment option. However, penicillamine has significant side effects and tolerability issues which has driven research into newer alternatives. Several pipeline drugs are under development which are expected to enter the market over the forecast period and capture market share from incumbent therapies.
Market key trends:
The Wilson’s disease treatment market has been witnessing a rising demand for drugs that offer improved efficacy and lower side effects. A key trend gaining traction in the market is the development of novel drugs for Wilson’s disease. For instance, Kadmon Holdings, Inc. is developing KD025, a HO1 inducer, which is currently in phase 2/3 clinical trials for the treatment of Wilson’s disease. The drug has the potential to improve the treatment landscape with its better efficacy and safety profile.
SWOT Analysis
Strength: Presence of established players with strong geographic presence and product portfolios.
Weakness: High costs associated with drug development and regulatory approvals.
Opportunity: Rising R&D investments and new product launches by key players.
Threats: Patent expiries of major drugs and entry of generic versions.
Key Takeaways
The global Wilson’s disease treatment market is expected to witness high growth, exhibiting CAGR of 6.3% over the forecast period, due to increasing prevalence of Wilson’s disease worldwide.
Regional analysis: North America dominated the global market in 2022 and is expected to continue its dominance over the forecast period. This is attributed to growing research activities for Wilson’s disease treatment in the US. However, Asia Pacific is anticipated to exhibit the fastest growth rate owing to rising awareness regarding Wilson’s disease and increasing healthcare expenditure in the region.
Key players operating in the Wilson’s disease treatment market are Valeant Pharmaceuticals International, Inc., Noblepharma Co., Ltd., Wilson Therapeutics AB, Kadmon Holdings, Inc., Merck & Co., Inc., VHB Life Science Ltd., Teva Pharmaceuticals USA, Inc., and Tsumura & Co. Kadmon Holdings, Inc. enjoys a significant market share due to its novel drug KD025 currently in phase 2/3 clinical trials.